1
|
Sousa IG, do Almo MM, Simi KCR, Bezerra MAG, Andrade RV, Maranhão AQ, Brigido MM. MicroRNA expression profiles in human CD3 + T cells following stimulation with anti-human CD3 antibodies. BMC Res Notes 2017; 10:124. [PMID: 28292330 PMCID: PMC5351193 DOI: 10.1186/s13104-017-2442-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 03/01/2017] [Indexed: 02/07/2023] Open
Abstract
Background Anti-CD3 therapy can induce immunosuppression by several non mutually exclusive mechanisms that have been proposed to explain the therapeutic effect the administration anti-CD3 mAb, but its immunoregulatory mechanism is still not completely clear. In T cells, microRNAs (miRNAs) regulate several pathways, including those associated with immune tolerance. Here, we report changes in miRNA expression in T cells following treatment with anti-human CD3 antibodies. Peripheral blood mononuclear cells were cultured in the presence of the monoclonal antibody OKT3 or a recombinant fragment of humanized anti-CD3. Following these treatments, the expression profiles of 31 miRNA species were assessed in T cells using TaqMan arrays. Results Eight of the tested miRNAs (miR-155, miR-21, miR-146a, miR-210, miR-17, miR-590-5p, miR-106b and miR-301a) were statistically significantly up- or down-regulated relative to untreated cells. Conclusions Stimulation of T cells with anti-human CD3 antibodies alters miRNA expression patterns, including of miRNA species associated with immune regulatory pathways. Electronic supplementary material The online version of this article (doi:10.1186/s13104-017-2442-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Isabel Garcia Sousa
- Molecular Pathology Graduation Program, Medicine Faculty, University of Brasilia, Brasilia, Brazil
| | - Manuela Maragno do Almo
- Molecular Pathology Graduation Program, Medicine Faculty, University of Brasilia, Brasilia, Brazil
| | | | | | | | - Andréa Queiroz Maranhão
- Department of Cell Biology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.,Institute for Immunology Investigation, A National Institute of Science and Technology, Brasilia, Brazil
| | - Marcelo Macedo Brigido
- Department of Cell Biology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil. .,Institute for Immunology Investigation, A National Institute of Science and Technology, Brasilia, Brazil.
| |
Collapse
|
2
|
Segovia M, Louvet C, Charnet P, Savina A, Tilly G, Gautreau L, Carretero-Iglesia L, Beriou G, Cebrian I, Cens T, Hepburn L, Chiffoleau E, Floto RA, Anegon I, Amigorena S, Hill M, Cuturi MC. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation. Am J Transplant 2014; 14:1021-1031. [PMID: 24731243 PMCID: PMC4629416 DOI: 10.1111/ajt.12708] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Revised: 12/18/2013] [Accepted: 01/07/2014] [Indexed: 01/25/2023]
Abstract
The administration of autologous (recipient-derived) tolerogenic dendritic cells (ATDCs) is under clinical evaluation. However, the molecular mechanisms by which these cells prolong graft survival in a donor-specific manner is unknown. Here, we tested mouse ATDCs for their therapeutic potential in a skin transplantation model. ATDC injection in combination with anti-CD3 treatment induced the accumulation of CD8(+) CD11c(+) T cells and significantly prolonged allograft survival. TMEM176B is an intracellular protein expressed in ATDCs and initially identified in allograft tolerance. We show that Tmem176b(-/-) ATDCs completely failed to trigger both phenomena but recovered their effect when loaded with donor peptides before injection. These results strongly suggested that ATDCs require TMEM176B to cross-present antigens in a tolerogenic fashion. In agreement with this, Tmem176b(-/-) ATDCs specifically failed to cross-present male antigens or ovalbumin to CD8(+) T cells. Finally, we observed that a Tmem176b-dependent cation current controls phagosomal pH, a critical parameter in cross-presentation. Thus, ATDCs require TMEM176B to cross-present donor antigens to induce donor-specific CD8(+) CD11c(+) T cells with regulatory properties and prolong graft survival.
Collapse
Affiliation(s)
- M. Segovia
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - C. Louvet
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - P. Charnet
- CRBM, CNRS UMR 5237, Montpellier, France
| | - A. Savina
- Institut Curie, Paris, France
,INSERM U932, Paris, France
| | - G. Tilly
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - L. Gautreau
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - L. Carretero-Iglesia
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - G. Beriou
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - I. Cebrian
- Institut Curie, Paris, France
,INSERM U932, Paris, France
| | - T. Cens
- CRBM, CNRS UMR 5237, Montpellier, France
| | - L. Hepburn
- Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
| | - E. Chiffoleau
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - R. A. Floto
- Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
| | - I. Anegon
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
| | - S. Amigorena
- Institut Curie, Paris, France
,INSERM U932, Paris, France
| | - M. Hill
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
,Corresponding authors: Marcelo Hill, , and Maria Cristina Cuturi,
| | - M. C. Cuturi
- ITUN, INSERM UMR_S 1064, Center for Research in Transplantation and Immunology, Nantes, France
,Corresponding authors: Marcelo Hill, , and Maria Cristina Cuturi,
| |
Collapse
|
3
|
Goto R, You S, Zaitsu M, Chatenoud L, Wood KJ. Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. Am J Transplant 2013; 13:1655-64. [PMID: 23750800 PMCID: PMC3790953 DOI: 10.1111/ajt.12272] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 03/08/2013] [Accepted: 03/31/2013] [Indexed: 01/25/2023]
Abstract
The engineered Fc-nonbinding (crystallizable fragment-nonbinding) CD3 antibody has lower mitogenicity and a precise therapeutic window for disease remission in patients with type 1 diabetes. Before anti-CD3 can be considered for use in transplantation, the most effective timing of treatment relative to transplantation needs to be elucidated. In this study anti-CD3F(ab')2 fragments or saline were administered intravenously for 5 consecutive days (early: d1-3 or delayed: d3-7) to mice transplanted with a cardiac allograft (H2(b)-to-H2(k); d0). Survival of allografts was prolonged in mice treated with the early protocol (MST = 48 days), but most were rejected by d100. In contrast, in mice treated with the delayed protocol allografts continued to survive long term. The delayed protocol significantly inhibited donor alloreactivity at d30 as compared to the early protocol. A marked increase in Foxp3(+) T cells (50.3 ± 1.6%) infiltrating the allografts in mice treated with the delayed protocol was observed (p < 0.0001 vs. early (24.9 ± 2.1%)) at d10; a finding that was maintained in the accepted cardiac allografts at d100. We conclude that the timing of treatment with anti-CD3 therapy is critical for inducing long-term graft survival. Delaying administration effectively inhibits the alloreactivity and promotes the dominance of intragraft Foxp3(+) T cells allowing long-term graft acceptance.
Collapse
Affiliation(s)
- R Goto
- Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of OxfordJohn Radcliffe Hospital, Oxford, United Kingdom
| | - S You
- Universite Paris Descartes, Institut National de la Santé et de la Recherche Médicale Unit 1013Paris, France
| | - M Zaitsu
- Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of OxfordJohn Radcliffe Hospital, Oxford, United Kingdom
| | - L Chatenoud
- Universite Paris Descartes, Institut National de la Santé et de la Recherche Médicale Unit 1013Paris, France
| | - KJ Wood
- Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of OxfordJohn Radcliffe Hospital, Oxford, United Kingdom,* Kathryn J. Wood,
| |
Collapse
|
4
|
Kuhns MS, Davis MM. TCR Signaling Emerges from the Sum of Many Parts. Front Immunol 2012; 3:159. [PMID: 22737151 PMCID: PMC3381686 DOI: 10.3389/fimmu.2012.00159] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2012] [Accepted: 05/27/2012] [Indexed: 11/30/2022] Open
Abstract
“How does T cell receptor signaling begin?” Answering this question requires an understanding of how the parts of the molecular machinery that mediates this process fit and work together. Ultimately this molecular architecture must (i) trigger the relay of information from the TCR-pMHC interface to the signaling substrates of the CD3 molecules and (ii) bring the kinases that modify these substrates in close proximity to interact, initiate, and sustain signaling. In this contribution we will discuss advances of the last decade that have increased our understanding of the complex machinery and interactions that underlie this type of signaling.
Collapse
Affiliation(s)
- Michael S Kuhns
- Department of Immunobiology, The University of Arizona College of Medicine Tucson, AZ, USA
| | | |
Collapse
|
5
|
Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood 2012; 120:1005-14. [PMID: 22723555 DOI: 10.1182/blood-2012-01-406827] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Omenn syndrome (OS) is an atypical primary immunodeficiency characterized by severe autoimmunity because of activated T cells infiltrating target organs. The impaired recombinase activity in OS severely affects expression of the pre-T-cell receptor complex in immature thymocytes, which is crucial for an efficient development of the thymic epithelial component. Anti-CD3ε monoclonal antibody (mAb) treatment in RAG2(-/-) mice was previously shown to mimic pre-TCR signaling promoting thymic expansion. Here we show the effect of anti-CD3ε mAb administration in the RAG2(R229Q) mouse model, which closely recapitulates human OS. These animals, in spite of the inability to induce the autoimmune regulator, displayed a significant amelioration in thymic epithelial compartment and an important reduction of peripheral T-cell activation and tissue infiltration. Furthermore, by injecting a high number of RAG2(R229Q) progenitors into RAG2(-/-) animals previously conditioned with anti-CD3ε mAb, we detected autoimmune regulator expression together with the absence of peripheral immunopathology. These observations indicate that improving epithelial thymic function might ameliorate the detrimental behavior of the cell-autonomous RAG defect. Our data provide important therapeutic proof of concept for future clinical applications of anti-CD3ε mAb treatment in severe combined immunodeficiency forms characterized by poor thymus function and autoimmunity.
Collapse
|
6
|
Miyahara Y, Khattar M, Schroder PM, Mierzejewska B, Deng R, Han R, Hancock W, Chen W, Stepkowski SM. Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells. Am J Transplant 2012; 12:1409-18. [PMID: 22420295 PMCID: PMC3365620 DOI: 10.1111/j.1600-6143.2012.04006.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
TCR specific antibodies may modulate the TCR engagement with antigen-MHC complexes, and in turn regulate in vivo T cell responses to alloantigens. Herein, we found that in vivo administration of mAbs specific for mouse TCRβ (H57-597), TCRα or CD3 promptly reduced the number of CD4(+) and CD8(+) T cells in normal mice, but H57-597 mAb most potently increased the frequency of CD4(+) Foxp3(+) Treg cells. When mice were injected with staphylococcal enterotoxin B (SEB) superantigen and H57-597 mAb, the expansion of SEB-reactive Vβ8(+) T cells was completely abrogated while SEB-nonreactive Vβ2(+) T cells remained unaffected. More importantly, transient H57-597 mAb treatment exerted long-lasting effect in preventing T cell responses to alloantigens, and produced long-term cardiac allograft survival (>100 days) in 10 out of 11 recipients. While Treg cells were involved in maintaining donor-specific long-term graft survival, T cell homeostasis recovered over time and immunity was retained against third party allografts. Moreover, transient H57-597 mAb treatment significantly prolonged survival of skin allografts in naïve recipients as well as heart allografts in skin-sensitized recipients. Thus, transient modulation of the TCRβ chain by H57-597 mAb exhibits potent, long-lasting therapeutic effects to control alloimmune responses.
Collapse
Affiliation(s)
- Y. Miyahara
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States
| | - M. Khattar
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States
| | - P. M. Schroder
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States
| | - B. Mierzejewska
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States
| | - R. Deng
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States,Organ Transplantation Center, 1 Affiliated Hospital, Sun-Yat Sen University, Guangzhou, China 510080
| | - R. Han
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States
| | - W.W. Hancock
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States
| | - W. Chen
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States,Correspondence: Wenhao Chen, PhD and Stanislaw M. Stepkowski, PhD. Department of Medical Microbiology and Immunology, University of Toledo-Health Science Campus, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614. Telephone 419-383-6681, Fax 419-383-3002, ;
| | - S. M. Stepkowski
- Department of Medical Microbiology and Immunology, University of Toledo Medical College, Toledo, OH 43614, United States,Correspondence: Wenhao Chen, PhD and Stanislaw M. Stepkowski, PhD. Department of Medical Microbiology and Immunology, University of Toledo-Health Science Campus, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614. Telephone 419-383-6681, Fax 419-383-3002, ;
| |
Collapse
|